CHDI FOUNDATIONCHDI

Accelerating Therapeutic Development for Huntington's Disease

  • Preclinical research
  • Scientific Publications
  • Community Resources
    • Materials
      • Research tools & reagents
      • Mouse Models
      • Clinical biorepository
    • Data sharing & infomatics
      • Preclinical informatics: HDinHD
    • Funding & partnerships
      • Academic Proposals
      • External Partnership Proposals
    • HD expertise & guidance
      • Independent Statistical Standing Committee
      • Clinical outcomes: Rating scales
      • Field guide to HD mouse models
  • News & Video
    • News
    • HD Therapeutics Conference
      • 2025 Presentations
      • 2024 Presentations
      • 2023 Presentations
      • 2022 Presentations
      • 2021 Presentations
      • 2020 Presentations
      • 2019 Presentations
      • 2018 Presentations
      • 2017 Presentations
      • 2016 Presentations
      • 2015 Presentations
      • 2014 Presentations
      • 2013 Presentations
      • 2012 Presentations
      • 2011 Presentations
    • Postcards
    • Events
  • About Us
    • The Foundation
    • People
    • Policies
      • Data, Reagents, and Biomaterials Sharing Policy
      • Publication Policy
      • Reimbursement of Publication Costs
      • Financial Support for Conferences, Meetings, or Workshops
      • Academic Overhead
      • Academic Salary Limits
      • Leave of Absence Policy
      • Eligible Personnel
  • Preclinical research
  • Scientific Publications
  • Community Resources
    • Materials
      • Research tools & reagents
      • Mouse Models
      • Clinical biorepository
    • Data sharing & infomatics
      • Preclinical informatics: HDinHD
    • Funding & partnerships
      • Academic Proposals
      • External Partnership Proposals
    • HD expertise & guidance
      • Independent Statistical Standing Committee
      • Clinical outcomes: Rating scales
      • Field guide to HD mouse models
  • News & Video
    • News
    • HD Therapeutics Conference
      • 2025 Presentations
      • 2024 Presentations
      • 2023 Presentations
      • 2022 Presentations
      • 2021 Presentations
      • 2020 Presentations
      • 2019 Presentations
      • 2018 Presentations
      • 2017 Presentations
      • 2016 Presentations
      • 2015 Presentations
      • 2014 Presentations
      • 2013 Presentations
      • 2012 Presentations
      • 2011 Presentations
    • Postcards
    • Events
  • About Us
    • The Foundation
    • People
    • Policies
      • Data, Reagents, and Biomaterials Sharing Policy
      • Publication Policy
      • Reimbursement of Publication Costs
      • Financial Support for Conferences, Meetings, or Workshops
      • Academic Overhead
      • Academic Salary Limits
      • Leave of Absence Policy
      • Eligible Personnel

May 7, 2010

CHDI Foundation, Inc. and the National Institute of Neurological Disorders and Stroke (NINDS) launch joint program to support the validation of novel therapeutic targets for Huntington’s disease

New York City, NY – CHDI Foundation, Inc. (CHDI) and the National Institute of Neurological Disorders and Stroke (NINDS) have released a funding opportunity announcement (FOA) regarding an extramural program to preclinically validate therapeutic targets for Huntington’s disease (HD). CHDI, a not-for-profit virtual biotech company that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of HD, will provide a $4.5 million gift to NINDS for “set aside” funds to support R01 research projects in addition to those financed within regular NINDS funding policies.

“This partnership between NINDS and CHDI creates an important opportunity for researchers to translate discoveries about the mechanisms of Huntington’s disease into candidate drugs and other potential treatments,” said NINDS Director Story Landis, PhD. NINDS, which is part of the National Institutes of Health (NIH), will be responsible for overseeing the review process to gauge the merit of the applications, as well as for final funding decisions, monitoring the scientific progress of the research, and post-award management.

“The NIH is the engine driving world-leading basic research to advance our fundamental understanding of disease that leads to effective therapies,” said Robi Blumenstein, President of CHDI Management. “We see enormous value in using the established, rigorous peer review mechanisms that NINDS has in place to identify high-quality projects to validate therapeutic targets that subsequently could be translated to benefit HD patients.”

Under the terms of their awards, grantees will be required to submit data developed within this program to the public database immediately following publication of results or within six months of termination of the grant award. Principal investigators will be encouraged, but not required, to share the NINDS progress reports with CHDI.

“The focus of the projects solicited in this program fits perfectly within CHDI’s mission. Our aim is to extend our support for established HD researchers as well as motivate new investigators to enter the HD research field” said Ignacio Munoz-Sanjuan, PhD, Vice President, Biology at CHDI Management.

Awards issued under this FOA are contingent upon the submission of a sufficient number of meritorious applications. In subsequent years, the amount of funding available will be announced in Notices published in the NIH Guide to Grants and Contracts. Applications under this program announcement with set aside (PAS) must be submitted by June 30, 2010, for review at the October 2010 council. Interested parties may find more information at the NINDS Funding Opportunities website –

www.ninds.nih.gov/funding/funding_announcements/allnew.htm

http://grants.nih.gov/grants/guide/pa-files/PAS-10-183.html

Post navigation

← The Public Library of Science, with support from CHDI Foundation Inc., has launched PLoS Currents: Huntington Disease CHDI Foundation, Inc to carry out High Q Foundation’s research activities in Huntington’s disease →
Connect with CHDI

Send Feedback

We appreciate any comments or questions on this page—our goal is to make this concise and helpful.

Join Our Mailing List
Terms of Use
Privacy Policy
Cookie Policy
Creative Commons License
Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 3.0 Unported License.

Click to read a letter from Robert Pacifici, CHDI CSO, regarding COVID-19